It is becoming more critical today for life science companies to stretch their dollars into pre-clinical research and ultimately, commercial viability. Pressures range from funding sources and partnerships to managing real estate and outsourcing options; all of these affect the strategic decisions start-up or growing biotech companies need to make.
Join our BioSciences Forum for this panel discussion which will review some of the many strategies and options biotech companies have at their disposal and the effects these decisions may or may not have on their ability to pivot and address new challenges with their research and platforms. At present, there are a number of alternatives when it comes to pre- and clinical work - including CROs, CDMO, and incubators. Companies must consider the relevance and timing of commercial lab space availability, construction costs and lead times, and investor requirements. Small companies are feeling the squeeze to provide clinical results, which brings new challenges and the need to rethink how things get done.
Our Speakers (Updated):
Chris Mansur, President of Azzur Consulting, Azzur Group
Chris Mansur currently serves as the President of Azzur Group’s Consulting division, which specializes in providing innovative quality and compliant solutions to the life sciences industry. Throughout his career, Chris has specialized in new and renovated facility startups, project management, commissioning & qualification, computer validation, implementation of quality systems, and application of quality risk management principles. He is passionate about the use of Phase-Appropriate GMPs to help companies solve problems that accelerate their product's lifecycle or project timeline. Chris holds a bachelor of science degree in Mechanical Engineering from Worcester Polytechnic Institute.
Leslie Lippard, Senior Director, Strategy & Portfolio Analytics, Alnylam Pharmaceuticals
Leslie is a Senior Director on the Strategy and Portfolio Analytics team at Alnylam and heads up Project Strategy. She joined Alnylam in 2019 and previously was at Genentech in San Francisco, where she was part of Genentech Research and Early Development, focusing on strategy for early stage assets. In past work lives, Leslie has variously been an entrepreneur, a salesperson, a market researcher, a strategy consultant, an engineer, and a factor worker. As a consultant, she served several early stage clients with a variety of specific challenges, including how to value very early stage IP for the purposes of fund raising, prioritizing investments and workstreams given balance sheet limitations, timing of fundraising, and partnering to support the commercialization of a first product. She has an undergraduate degree in physics from Caltech and an MBA from the University of Oregon and brings a decidedly west-coast perspective. Outside of work, she enjoys art, nature and all forms of two-wheeled transportation.
Generously Sponsored by:
North Shore Technology Council is a 501(c)6 non-profit organization. 100 Cummings Center, Suite 223-F Beverly, MA 01915.
Contact us at administrator@nstc.org.
